SavedAdd your journal

Journals / Türk Nöroşirürji Dergsi / 2017 / Cilt: 27 - Sayı: 1

Treatment Options in Medulloblastoma

Medulloblastomada Tedavi Seçenekleri

Tuncer TURHAN
Elif BOLAT
Pages
31–37
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this manuscript we focused on the generally accepted treatment methods and expectations for the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Medulloblastomas are primary malignant embryonal tumours of the central nervous system.They are the most common in childhood and mostly found in posterior fossa.
📊
Key Findings & Data:Patients are currently classified as being either standard or high risk in order to stratify treatment.
💡
Conclusion & Impact:In this manuscript we focused on the generally accepted treatment methods and expectations for the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Medulloblastomas are primary malignant embryonal tumours of the central nervous system.They are the most common in childhood and mostly found in posterior fossa. Patients are currently classified as being either standard or high risk in order to stratify treatment. Treatment of medulloblastoma include combination of surgery, chemotherapy and radiotherapy. In this manuscript we focused on the generally accepted treatment methods and expectations for the future.

Özet

Medulloblastomalar merkezi sinir sisteminin primer malign embriyonel tümörleridir. Çoğunlukla çocukluk çağında görülürler ve posterior fossaya yerleşme eğilimindedirler. Tedavinin belirlenmesi için hastalar standart ve yüksek risk grubu olarak iki ayrı grupta toplanmaktadırlar. Tedavinin temelini ise cerrahi girişim, kemoterapi ve radyoterapi kombinasyonu oluşturmaktadır. Bu yazıda hastalığın tedavisi için genel olarak kabul görmüş tedavi yöntemleri ve gelecekten beklentiler özetlenmeye çalışılmıştır.

🔖

Cite This Article

TURHAN, T., BOLAT, E. (2022). Treatment Options in Medulloblastoma. Türk Nöroşirürji Dergsi, Cilt: 27 - Sayı: 1, 31–37. https://ajindex.com/articles/637382

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Adamski J, Ramaswamy V, Huang A, Bouffet E: Advances in managing medulloblastoma and intracranial primitive neuroectodermal tumors. F1000 Prime Rep 6:56, 2014 2. Bailey P, Cushing H: Medulloblastoma cerebelli: A common type of midcerebellar glioma in childhood. Arch Neurol Psychiatry 14:192-224, 1925 3. Bartlett F, Kortmann R, Saran F: Medulloblastoma. Clin Oncol (R Coll Radiol) 25:36-45, 2013 4. Breen SL, Kehagioglou P, Usher C, Plowman PN: A comparison of conventional, conformal and intensity-modulated coplanar radiotherapy plans for posterior fossa treatment. Br J Radiol 77: 768-774, 2004 5. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29: 1424-1430, 2011 6. De Braganca KC, Packer RJ: Treatment options for medulloblastoma and CNS primitive neuroectodermal tumor (PNET). Curr Treat Options Neurol 15:593-606, 2013 7. Deutsch M, Thomas PR, Krischer J, Boyett JM, Albright L, Aronin P, Langston J, Allen JC, Packer RJ, Linggood R, Mulhern R, Stanley P, Stehbens JA, Duffner P, Kun L, Rorke L, Cherlow J, Freidman H, Finlay JL, Vietti T: Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 24:167-176; discussion 176- 167, 1996 8. Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, Abromowitch M, Sposto R, Finlay JL: Outcome of children less than three years old at diagnosis with nonmetastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer 50:1169-1175, 2008 9. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002 10. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC: Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449, 2004 11. Ellison DW, Onilude OE